← Back to Search

Cancer Vaccine

ALVAC-HIV Vaccine for HIV Prevention

Phase 1

Waitlist Available

Led By Mary Marovich

Research Sponsored by Walter Reed Army Institute of Research (WRAIR)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Volunteers must be healthy adults from 18 to 55 years of age

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will test different ways of giving the ALVAC HIV-1 vaccine to see if it is safe and effective.

Who is the study for?

This trial is for healthy US adults aged 18 to 55 who are not pregnant, breastfeeding, allergic to eggs or neomycin, taking certain prescriptions, HIV-positive, or at high risk for HIV infection.Check my eligibility

What is being tested?

The study is testing the best way to administer a potential HIV vaccine called ALVAC-HIV-1 (vCP205) in people who do not have HIV.See study design

What are the potential side effects?

Potential side effects of the ALVAC-HIV-1 vaccine may include typical reactions seen with other vaccines such as soreness at injection site, fever, fatigue and muscle pain.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a healthy adult between 18 and 55 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 1Eligibility criteria met

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Walter Reed Army Institute of Research (WRAIR)Lead Sponsor

107 Previous Clinical Trials

36,728 Total Patients Enrolled

Mary MarovichPrincipal Investigator

Media Library

ALVAC-HIV-1 (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT00013572 — Phase 1

Human Immunodeficiency Virus Infection Research Study Groups:

Human Immunodeficiency Virus Infection Clinical Trial 2023: ALVAC-HIV-1 Highlights & Side Effects. Trial Name: NCT00013572 — Phase 1

ALVAC-HIV-1 (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00013572 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Am I eligible to join this clinical experiment?

"Candidates between 18 and 55 years of age must have HIV seronegativity to be eligible for this trial. A total of 36 candidates are being recruited at the moment."

Answered by AI

Has this particular treatment been sanctioned by the U.S. Food and Drug Administration?

"Due to a lack of evidence for safety and efficacy, this treatment has been evaluated with a score 1 on the Power scale. This is indicative that it is at Phase 1 in clinical trials."

Answered by AI